FA
NBIX icon

Fountainhead AM’s Neurocrine Biosciences NBIX Stock Holding History

Fountainhead AM’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Buy
+84
New +$12.5K 0.01% 181
2021
Q1 		– Sell
-2,124
Closed -$204K – 61
2020
Q4 		$204K Buy
+2,124
New +$205K 0.13% 51

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fountainhead AM's NBIX Position: Q2 2026 in Review

Fountainhead AM opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 84 shares worth $14.2K. The stake represents 0.01% of the portfolio and ranks #181 among its holdings. This is a return to the name: Fountainhead AM previously reported a position in NBIX as recently as Q4 2020.

Fountainhead AM first reported a position in NBIX in Q4 2020 and has held it in 2 quarters since. The position peaked at $204K in Q4 2020. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fountainhead AM held 84 shares of Neurocrine Biosciences worth $14.2K as of Q2 2026.
  • Neurocrine Biosciences was a new Fountainhead AM position in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Fountainhead AM's portfolio in Q2 2026, its #181 holding.
  • Fountainhead AM first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 2 quarters since.
  • Fountainhead AM's Neurocrine Biosciences position peaked at $204K in Q4 2020.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fountainhead AM's 13F filing for Q2 2026, filed 3 Aug 2026.